LEO Pharma submits NDA for aerosol foam formulation to treat patients with plaque psoriasis

LEO Pharma announces it has submitted a New Drug Application (NDA) for calcipotriene and betamethasone dipropionate aerosol foam, 0.005%/0.064%, to the U.S. Food and Drug Administration (FDA) for the treatment of plaque psoriasis.

The first aerosol foam formulation of the fixed combination calcipotriene/betamethasone dipropionate has been developed with the aim of improving treatment for patients with plaque psoriasis - the most common clinical form of psoriasis.

The regulatory submission in the US is based on studies of patients with plaque psoriasis. These include the Phase 3a PSO-FAST study which evaluated efficacy and safety at four weeks[1] and the Phase 2 MUSE safety study.[2]

Barbara J. Osborne, President and CEO, commented:

"Psoriasis is a chronic, debilitating disease. Patients with inadequately managed plaque psoriasis can experience substantial burden of illness, with similar reductions in quality of life to those experienced by patients with diabetes or cancer.

With the regulatory submission announced today, we are taking a step further towards providing additional topical treatment options for people living with psoriasis."

Regulatory filings in Europe and other countries are planned during the course of 2015 and 2016.

With this latest submission, LEO Pharma demonstrates a strong commitment to dermatology.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
At-home phototherapy proves effective for psoriasis treatment